MEIS-1 level in unresectable hepatocellular carcinoma can predict the post-treatment outcomes of radiofrequency ablation
Metrics: PDF 1360 views | HTML 2402 views | ?
Hui Xie1,2, Haipeng Yu1, Shengtao Tian2, Xueling Yang1, Ximing Wang2, Huaming Wang2 and Zhi Guo1
1Department of Interventional Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Cancer Research Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300070, PR China
2Department of interventional therapy, 302 Hospital of People's Liberation Army, Beijing 100039, PR China
Zhi Guo, email: email@example.com
Huaming Wang, email: firstname.lastname@example.org
Keywords: RFA; MEIS-1; unresectable HCC; prognosis
Received: August 29, 2017 Accepted: December 01, 2017 Epub: January 11, 2018 Published: March 16, 2018
Radiofrequency ablation (RFA) is a local-ablative therapy for unresectable hepatocellular carcinoma (HCC). At present, there is no predictive marker for RFA treatment outcomes. This work aimed to valuate myeloid ecotropic viral integration site 1 (MEIS-1) in predicting post-RFA treatment outcomes of unresectable HCC patients. The time to progression (TTP) and overall survival (OS) of 81 HCC patients who received RFA treatment were measured. The protein level of MEIS-1 in tumor specimens was measured by western blot. The role of MEIS-1 in RFA-treating HCC in vivo growth nude mouse model was examined via PET/CT imaging. Higher level of MEIS-1 in tumor tissue is associated with better RFA treatment outcomes. The median TTP was 9.0 (95% confidence interval [CI]: 6.8–11.3) months in patients with high MEIS-1 expression (n = 43) versus 6.0 (95% CI: 4.6–7.4) months in patients with low MEIS-1 expression (n = 38). Moreover, in rodent HCC model we found overexpression of MEIS-1 enhanced the anti-tumor effect of RFA treatment. We conclude that high level of MEIS-1 expression predicts better RFA treatment outcome in HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.